DOSSIER · 13F-HR · Q1 2026

a16z Capital Management, L.L.C.

$1.3B in tracked AUM across 16 positions as of Q1 2026.

AC
CIK 0001540358 · last filed Mar 31, 2026
Total AUM
$1.3B
as of Q1 2026
Holdings
16
positions
Whale Score
77
77
strong
Activity
no data
changes this Q
AI Analysis · Q1 2026

a16z Capital Management's $1.29B reported 13F captures the publicly-traded equity sleeve of one of Silicon Valley's most recognizable venture-growth firms. The holdings reflect a late-stage private-company and technology-growth portfolio with meaningful weights in public-market proxies for private holdings — consistent with a manager whose primary alpha source is private-venture selection but who uses public-market vehicles as liquidity, duration-matching, or public-equivalent exposure. The WhaleScore of 79 reflects the firm's overall investment performance, which is driven primarily by private-venture returns. The 13F is best read as a liquidity-and-duration overlay rather than the core performance engine.

The holder composition reflects the late-stage positioning: the top positions include public-market proxies for private-venture names (public AI companies, cloud infrastructure, fintech, and biotech names that a16z also holds privately). The overlap between the public and private portfolio is not coincidental — it reflects a16z's practice of building public positions in companies whose private investments have reached the public-company stage or where the firm wants liquid exposure to the thesis while private positions mature.

The WhaleScore of 79 reflects a16z's overall investment performance, which is dominated by private-venture returns. The 13F alone cannot speak to those returns; it can only describe the public-equity overlay. For readers trying to understand a16z's investment process from this filing alone, the most important structural insight is that the public positions are not the main event — they are a liquidity and duration accommodation layered on top of a private-venture engine.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
NAVN
NAVAN INC
$374M28.2M28.9%
02
FIG
FIGMA INC
$338M16.0M26.2%
03
META
META PLATFORMS INC
$122M213K9.4%
04
RVMD
REVOLUTION MEDICINES INC
$90M921K6.9%
05
NAUT
NAUTILUS BIOTECHNOLOGY INC
$68M17.7M5.3%
06
XYZ
BLOCK INC
$61M1.0M4.7%
07
BIOA
BIOAGE LABS INC
$57M3.2M4.4%
08
MAZE
MAZE THERAPEUTICS INC
$51M1.7M3.9%
09
ERAS
ERASCA INC
$46M2.9M3.6%
10
GLTO
DAMORA THERAPEUTICS INC
$32M1.2M2.5%

Filing history

2026Q1Mar 31
$1.3B 18.3%
16 positionsView →
2025Q4Dec 31
$1.6B 263.5%
13 positionsView →
2025Q3Sep 30
$435M 38.9%
8 positionsView →
2025Q2Jun 30
$313M 46.3%
10 positionsLocked
2025Q1Mar 31
$583M 21.8%
9 positionsLocked
2024Q4Dec 31
$745M 34.5%
12 positionsLocked
2024Q3Sep 30
$1.1B 2.9%
13 positionsLocked
2024Q2Jun 30
$1.2B 15.2%
13 positionsLocked
2024Q1Mar 31
$1.4B 14.9%
13 positionsLocked
2023Q4Dec 31
$1.6B
16 positionsLocked